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Abstract
Background: Over the last few decades, canine and feline thelaziosis caused by Thelazia callipaeda eye worms has
gained the attention of the veterinary community due to the spread of this ocular infestation in geographical areas
previously regarded as non endemic. The therapeutic efficacy of milbemycin oxime/praziquantel tablets
(Milbemax
W) against T. callipaeda was tested in naturally infested dogs and cats.
Methods: From January 2009 to July 2011 a placebo controlled and randomized field study was conducted in T.
callipaeda endemic areas of Switzerland (CH) and Italy (ITA) involving client-owned animals. Dogs (n=56) and cats
(n=31) were physically examined at enrolment Day 0 (D0) and twice afterwards (D7 and D14). Infested animals
were orally treated with Milbemax
W or with placebo tablets on D0 and, if an animal was found still infested with T.
callipaeda, also on D7. On D14 nematodes were flushed from the conjunctiva, identified and counted.
Results: Out of 56 dogs, 43 were included in the statistical analysis, whereas 13 were excluded because the
products under investigation were not administered with food, as required by the label. On D7 and D14, 72.7% and
90.9% of treated dogs were eye worm free, whereas in the placebo group 95.2% and 76.2% still harbored
nematodes, resulting in a mean percentage worm count reduction for the Milbemax
W group of 86.1% and 96.8%,
respectively. Both results were significantly higher (p=0.0001) than the placebo group. Out of the 31 cats included
in the study at D7 and D14, 53.3% and 73.3% treated with Milbemax
W were free of T. callipaeda, while 81.3% and
73.3 in the placebo group were still harbouring eye worms, resulting in a mean percentage worm count reduction
for the treated group of 62.2% and 80.0%, respectively. Both results were significantly higher (p=0.0106 and
p=0.0043) than the placebo group.
Conclusions: The commercial formulation of milbemycin oxime at the minimal dose of 0.5 mg/kg and 2 mg/k in
dogs and cats, respectively, showed a high therapeutic efficacy in curing T. callipaeda infestations. The advantages
of an oral application are additionally increased by the large spectrum of activity of praziquantel and milbemycin
oxime against Cestodes and Nematodes infesting dogs and cats.
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Thelazia callipaeda (Spirurida, Thelaziidae) is a nema-
tode infesting the eyes of dogs, cats, rabbits, wild carni-
vores and humans [1]. This parasite has been commonly
known as the “oriental eye worm” because of its occur-
rence, mostly in human beings, in far Eastern countries
such as Thailand [2], China [3] and Japan [4]. Nowadays,
it is evident that T. callipaeda is also endemic through-
out Europe infesting domestic and wild carnivores in
Italy [5,6] and Switzerland [7], and domestic animals in
France [8,9], Germany [10,11], and Spain [12]. Import-
antly, human cases of thelaziosis in Europe have been
recorded in Italy and France [13].
Since the incrimination of Phortica variegata (Diptera,
Drosophilidae) as a vector of T. callipaeda in Europe
under laboratory [14] and natural conditions [15], the
knowledge on this nematode and its vector has been
greatly enhanced. The adult whitish nematodes (about
0.5–2 cm) and first stage larvae (L1) localize under the
third eyelid provoking lacrimation, conjunctivitis or even
keratitis and corneal ulcer [16]. L1s are released by the
adult worms into the conjunctival secretions of infested
animals and they are ingested by P. variegata flies while
feeding on animal eyes, developing into the infective
third stage larvae (L3) within about 3 weeks [17].
The parasitic stages of T. callipaeda (i.e., adults and
larvae) may be removed mechanically by rinsing the con-
junctival sac with sterilized saline fluids or by collecting
the adults with fine forceps or cotton swab; however,
worm removal may be incomplete. Antiparasitic drugs,
such as macrocyclic lactones (e.g., moxidectin) have been
proven efficacious in treating thelaziosis by ocular instil-
lation [18,19]. For compliance reasons it may be recom-
mended to use systemic macrocyclic lactones licensed
for dogs and cats, such as the spot-on formulation con-
taining moxidectin (Advocate
W, Bayer HealthCare AG)
[20], or oral formulations containing milbemycin oxime
(Interceptor
W, Milbemax
W, Program Plus
W, Sentinel
W,
Novartis Animal Health) [21]. Interceptor
W showed a
good therapeutic and prophylactic efficacy in treating
thelaziosis in naturally infested dogs [21].
Due to the increasing attention of pet owners and practi-
tioners on canine and feline thelaziosis and to the spread
of this ocular infestation in geographical areas previously
regarded as non endemic, new therapeutic options are
solicited. Thus, the aim of this work was to evaluate the
therapeutic efficacy of a commercial oral formulation of
milbemycin oxime/praziquantel (Milbemax
W -N o v a r t i s
Animal Health) in dogs and cats naturally infested with T.
callipaeda.
Methods
The efficacy of Milbemax
W (Novartis Animal Health) was
evaluated in a placebo controlled, multicentric, blinded
and randomized field study conducted in Switzerland
(CH) in the Mendrisiotto region (Southern Ticino,
101 km
2, latitude 45°52 N and latitude 8°59 E, altitude ran-
ging from 277–571 m above sea level), and in Italy (ITA)
in the Basilicata region (Southern Italy, 9‘992 km
2,l a t i -
tude: 30° and 41°N; longitude 15° and 16° E, altitude ran-
ging from 548–1367 m asl).
Dogs (Figure 1) and cats (Figure 2) naturally infested with
T. callipaeda were enrolled from January 2009 to June
2011 (CH) and from October 2010 to July 2011 (ITA). The
study was conducted under Good Clinical Practice, accord-
ing to EMEA VICH GL9, GL7 and GL19. The trial was
performed after obtaining written animal owner con-
sent, animal trial permissions of the Ticino cantonal
(Switzerland) veterinary office (permission numbers 04/
2009 and 05/2009) and of the Italian authorities (permis-
sion numbers MoH Italy n. DGSA 0018416-P-14/10/2010).
Animals
All dogs and cats were client-owned, living in T. calli-
paeda endemic areas, of both sexes, various breeds, at
least 6 weeks old and weighing 0.5 kg or more at time of
inclusion. Animals were required to be infested with a
minimum of one worm in one conjunctival pouch and
living outdoors or regularly going outdoors. Testing for
infestation of Dirofilaria immitis was done in Southern
Ticino, being a heartworm endemic area, prior to inclu-
sion in accordance with Milbemax
W label content. Only
D. immitis negative dogs were included in the study.
Procedures
Dogs and cats were physically examined by the veterinar-
ian at enrolment (D0) and then at two follow-up visits,
(D7 and D14). A general physical examination was
Figure 1 Conjunctivits in a dog with Thelazia callipaeda. Adult
specimens of Thelazia callipaeda provoking conjunctivitis and
mucopurulent discharge in the eye of a dog from Italy (Basilicata).
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the animals. This examination also included body weight
(b.w.) determination on D0 and D14. A blood sample was
collected on day 0, before the treatment, for baseline
haematology and clinical chemistry. In Southern Ticino the
presence of D. immitis antigen (Dirocheck
(R), Synbiotics)
and microfilariae (Knott’st e s t )w a sa s s e s s e di nd o g s .A t
each visit, both eyes were examined for the presence of eye
worms by clinical inspection of the conjunctival pouch, in-
cluding a thorough examination underneath the third eye-
lid using a cotton swab. If necessary, 2 drops per eye of a
local anaesthetic (oxybuprocaine hydrochloride solution,
Novesin
W 0.4%, Omnivision) were applied into the con-
junctival pouches. Clinical signs indicative of eye worm in-
festation (e.g., lacrimation, conjunctivitis, ocular discharge,
keratitis, ulcers) were recorded and classified as absent
mild, moderate or severe. A fluorescein test to diagnose
ulcers was only performed if the animal was suspected to
have ulcers. Worms were counted in each eye separately
and the infestation intensity categorized into very mild (1
worm), mild (2–5 worms), moderate (6–10 worms) and
severe (>10 worms).
On D0 dogs and cats were randomly allocated to treat-
ment or control group by a random treatment allocation
plan and orally treated according to body weight, follow-
ing the label instructions of the commercial formulations
of Milbemax
W in both countries. In order to keep the
blinding on the treatment details, even though both pro-
ducts (i.e., the milbemycinoxime/praziquantel and the
placebo tablets) were comparable in appearance, a tech-
nician, different from the veterinarian that performed
clinical evaluations, was responsible for the administra-
tion of the product and the storage of all test product
related documentation.
On D7, if an animal was still found to be infested with T.
callipaeda, a re-treatment with the same product at the
same dose was administered. On D14, at the final visit, the
conjunctival pouches were flushed with 5 ml of saline solu-
tion (0.9% NaCl) to collect larval stages of the parasite that
were identified and counted, following centrifugation
(5 min at 2000 g) and microscopic examination (40×).
During the study period animals were observed daily
by their owners for health abnormalities and physically
examined by the veterinarian in case of adverse events. If
eye worms were still detected after D14, parasites were
mechanically removed or animals were treated with an
injectable solution of moxidectin 1 per cent (Cydectin
W,
Fort Dodge Animal Health) administered by ocular ad-
ministration as previously described [18].
Statistical analysis
Data were statistically examined using SAS
W Version 9.2
(SAS Institute, Cary, NC, USA). Summary statistics includ-
ing arithmetic and geometric mean, minimum, maximum
and median were provided for all counts, percentages or
continuous parameters of interest. Primary efficacy object-
ive was to compare the Milbemax
W group with the placebo
group with respect to clinical cure (therapeutic efficacy), i.
e., complete elimination of adult eye worms, seven and
fourteen days after treatment. Secondary efficacy objective
was to compare the treatment groups with respect to
worm count reduction and reduction of severity and/or
presence of clinical signs caused by eye worm infestation.
Worm count reduction was calculated for each animal as
follows: % reduction[t]=100 × (WC[to] – WC[t])/WC[to],
where WC[to]=baseline worm count before treatment
and WC[t]=worm count at time t after treatment. Fisher’s
exact test was applied for the statistical comparison of clin-
ical cure rates and infestation frequencies between treat-
ment groups at different study days. Worm count
reduction percentages were analyzed by analysis of vari-
ance methods if the assumption of normal distribution
was satisfied on original scale or after transformation.
Otherwise, Mann–Whitney U test was performed to com-
pare the treatment groups. Adverse events observations
were summarized and Fisher’s exact test was applied for
the statistical comparison between groups. The level of sig-
nificance was set at p=0.05. Tests were performed two-
sided.
Results
Dogs
Out of 56 dogs, which fulfilled the inclusion criteria, 43
(19 CH, 23 ITA) were included in the statistical analysis.
Thirteen dogs were excluded because the investigational
products (Milbemax
W or placebo) were administered
without any food, thus not as per the recommendations
on the package leaflet. The included dogs were between
Figure 2 Thelazia callipaeda in the eye of a cat. Eye of a cat from
Basilicata infested with several adult specimens of Thelazia callipaeda.
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neutered) and 17 were females (12 intact, 5 spayed) and
they were of various breeds (n=24), including crossbreds
(n=19). Data on the worm count reductions are reported
in Table 1. On D0, dogs treated with Milbemax
W (n=22)
and dogs of the placebo group (n=21) harbored a mean
(arithmetic) of 6.14 and of 6.0 worms, respectively. The
percentage of animals harbouring worms after treatment
was significantly different (p=0.0001) between the groups,
in favor of the Milbemax
W treated group. The mean per-
centage worm count reduction was significantly higher for
the Milbemax
W group than for the placebo group
(p=0.0001) on D7 and D14. The mean number of worms
harbored by treated dogs was 1.36 and 0.14 on D7 and
D14, respectively, while worm burdens of dogs of the pla-
cebo group were 5.71 and 5.38, respectively, with these dif-
ferences being significant (p=0.0001) at D7 and D14, but
not at D0 (p=0.4054). At D14 T. callipaeda larval stages
were detected only in 3 dogs of the placebo group. Fre-
quencies and percentages of clinical parameters indicative
of eye worm infestation were not different between the
groups.
Cats
A total of 31 cats (11 CH, 20 ITA) aging between
8 months and 14 years old, corresponded to the inclu-
sion criteria and were included in the analysis. Of these,
19 were males (10 intact, 9 neutered) and 12 females (11
intact, one spayed). Data on the worm count reductions
are reported in Table 2. At Day 0, treated (n=15) and
untreated (n=16) cats harboured a mean (arithmetic) of
2.40 and of 2.38 worms, respectively. At D14, the num-
ber of animals free of T. callipaeda was higher in the
treated group, with this difference being significant
(p=0.0268). The mean percentage worm count reduc-
tion for the Milbemax
W group was significantly higher
(p=0.0106 and p=0.0043) than the ones of the placebo
group, on D7 and D14, respectively. The worm counts
for the Milbemax
W group were significantly lower than
for the placebo group at D7 (0.93, p=0.230) and 14
(0.80, p=0.0129), while there was no significant differ-
ence on D0 (p=0.4530). In 3 cats from the placebo
group, larval stages could be found on D14. The pres-
ence of lacrimation on D0 was registered for 26.7% and
37.5% of the cats from the Milbemax
W and the placebo
group, respectively. This difference was not significant
(p=0.7043).
On D7 lacrimation was detected in 6.7% and 43.8% of
the cats of the Milbemax
W and of the placebo group,
with this difference being significant (p=0.0373), in con-
trast to data obtained on D0 (p=0.7043).
Discussion
The commercial formulation of milbemycin oxime
(Milbemax
W)a tt h em i n i m a ld o s eo f0 . 5m g / k ga n d
2 mg/kg b.w. for dogs and cats, respectively, also con-
taining praziquantel (5 mg/kg b.w.), showed a high
therapeutic efficacy in curing T. callipaeda in naturally
infested animals. In dogs the efficacy was 72.7% and
90.9% after a single or two treatments, at a weekly inter-
val, both significantly differing from the placebo group.
In cats, the therapeutic efficacy was 53.3% and 73.3%
after a single or two treatments, at a weekly interval. It
is known that praziquantel is not efficacious against
nematodes. Since both actives of Milbemax
W,m i l b e m y -
cin oxime and praziquantel, are well established on the
market and known not to interfere with each other, it
can be assumed that other formulations containing mil-
bemycin oxime alone or in combination with other
actives (e.g., Interceptor
W, Sentinel
W, Sentinel Spec-
trum
W and Program Plus
W; all Novartis Animal Health)
m a yb ee f f i c a c i o u sa g a i n s tT. callipaeda. Furthermore,
Table 1 Worm count reduction in dogs infested with Thelazia callipaeda after oral treatment with milbemycin
oxime/praziquantel
Mean number of worms
per dog (n, range)
Animals without worms (n, %) Worm count reduction (%)
Study day 0 Study day 7 Study day 14 Study day 7 Study day 14
Milbemax
W group (n=22) 6.14 (1–22) 16 (72.7%)* 20 (90.9%)* 86.1%* 96.8%*
Placebo group (n=21) 6.0 (1–22) 1 (4.8%) 5 (23.8%) 10.8% 27.5%
* significant difference between milbemycin oxime/praziquantel-group and placebo-group.
Table 2 Worm count reduction in cats infested with Thelazia callipaeda after oral treatment with milbemycin
oxime/praziquantel
Mean number of worms per cat (n, range) Animals without worms (n, %) Worm count reduction (%)
Study day 0 Study day 7 Study day 14 Study day 7 Study day 14
Milbemax
W group (n=15) 2.40 (1–11) 8 (53.3%) 11 (73.3%)* 62.2%* 80.0%*
Placebo group (n=16) 2.38 (1–9) 3 (18.8%) 4/15 (26.7%) 20.0% 28.0%
* significant difference between Milbemax
W-group and placebo-group.
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the final host, an accurate dosing to ensure optimal
blood concentrations of milbemycin oxime is needed to
reach efficacious concentrations of the product in the
conjunctives. This may explain the reasons for a higher
efficacy of the product after a second treatment one
week after the first, as also suggested by the results of a
preliminary study on T. callipaeda naturally infested
animals [21]. A lower efficacy observed on the 13 dogs
(excluded from the statistical analysis) in which the
treatment was administered without food, highlights the
importance of a correct administration of the drug.
This study first evaluated the therapeutic efficacy of mil-
bemycin oxime and praziquantel against T. callipaeda in
cats. In addition, on the basis of a previous study in which
the monthly administration of milbemyin oxime in dogs
was highly effective (96.7%) for the prophylaxis of T. calli-
paeda [21], it may be argued that a similar prophylactic ef-
fect might occur in cats. This hypothesis deserves to be
further tested under field conditions. Treatment of thela-
ziosis is an important issue in animals living in endemic
areas, such as Basilicata in Italy (prevalence up to 60%;
[6]), or Spain (prevalence of 39.9%; [12]) and Switzerland
(prevalence up to 5%; [7]). An efficacious treatment against
T. callipaeda is useful for pet owners considering the
spread of the parasite in areas previously regarded as non
endemic, such as France [9] and Spain [12].
The reasons for such an increase in cases of thelaziosis
in dogs and cats throughout Europe are unknown, but it
could be related to the spread of vector populations as
well as to the occurrence of the infestation in wildlife
species (e.g., foxes, wolves, beech martens and brown
hares), which act as reservoirs for T. callipaeda [5].
Therefore, domestic animals which are traveling together
with their owners from non-endemic to areas endemic
for T. callipaeda should be treated since they are at risk
of acquiring thelaziosis, as reported for some dogs in
France or Germany [10,22]. Thus, monthly anthelmintic
treatments, which are already recommended as a control
strategy for dirofilarioses and other helminth infestations
(e.g. see ESCCAP.org), should be considered for animals
living in areas endemic for T. callipaeda in order to
eliminate larval stages soon after their transmission from
the drosophilid flies, thus interrupting the host-parasite
transmission chain [17,23]. The high level of efficacy
demonstrated in the current study suggests that further
investigations should be carried out in order to test the
effectiveness of the product when administered monthly
during the risk season, in preventing T. callipaeda infes-
tations in dogs and cats.
In addition, since Milbemax
W-tablets for cats are flavor
coated and chewable tablets are available for dogs, the oral
formulations are very easy to apply, compared to the non-
licensed local instillation of antiparasitic drugs [18,19] or
to the mechanical removal of parasites from eyes. This es-
pecially applies when dealing with non-cooperative dogs
and cats, where restraining them for manipulations around
the eyes or even for spot-on applications is particularly dif-
ficult and bears the risk of trauma. Furthermore, wet coats
or rainy days are reported to reduce the efficacy of topical
administrations [20], a problem that is avoided by the drug
administration per os.
Conclusion
The commercial formulation of milbemycin oxime at the
minimal dose of 0.5 mg/kg and 2 mg/kg milbemycin
oxime for dogs and cats, respectively, showed a high thera-
peutic efficacy in curing T. callipaeda infestations. The
advantages of an oral application of Milbemax
W are add-
itionally increased by the large spectrum of activity of
praziquantel and milbemycin oxime against Cestodes and
Nematodes infesting dogs and cats.
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